By Kelly Cloonan

Agilent Technologies got approval to expand the use of a cancer test to additional tumor types from the Food and Drug Administration.

The laboratory technologies company said Tuesday the FDA approved PD-L1 testing for use on the Dako Omnis platform, a technology used to diagnose diseases, to help identify patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer and gastric or gastroesophageal junction who may be eligible for treatment with Keytruda.

The approval expands access to PD-L1 testing to four additional tumor types, adding to previous approvals for non-small cell lung cancer and head and neck squamous cell carcinoma. Those initial approved indications were only available on the Autostainer Link 48 platform and are now also approved for the Dako Omnis platform, allowing labs to consolidate testing across more tumor types within a single Dako Omnis workflow, the company said.

PD-L1 was developed by Agilent in partnership with Merck as a companion diagnostic for Merck's Keytruda.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

June 02, 2026 16:43 ET (20:43 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.